IRCT201104266302N1已完成3 期
Efficacy analysis of Recombinant factor VIIa (Aryogen) in Comparison with Novoseven® on patients with congenital FVII deficiency
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 years 至 80 years（—）
- 性别
- All
入选标准
- •known case of congenital FVII deficiency that frequency of his/her bleeding episodes more than one per month,age older than 2,gender: male or female,proper IV line for drug injection,Exclusion criteria: Presence of any congenital or acquired coagulopathy disorders except for congenital F VII deficiency, liver disease (hepatitis), uremia, malignancy, vitamin K deficiency, having received Novoseven® as prophylactic therapy in congenital FVII deficiency since one month ago,severe atherosclerotic disease,any local pathology that predisposes the patient to bleeding, presence of antibody against FVII,Platelet count lower than 50000
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Efficacy analysis of Recombinant factor VIIa (Aryogen) in Comparison with Novoseven® on patients with congenital hemophilia A/B with inhibitorscongenital hemophilia A/B with inhibitors.Hereditary factor VIII deficiency, Hereditary factor IX deficiencyD66, D67IRCT201202106302N2AryoGen Biopharma Company66
已完成
3 期
Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation ActivationHemophilia ANCT00375323Medical University of Vienna
进行中（未招募）
不适用
Efficacy and safety of factor VIIa eptacog alfa, Novoseven on rebleeding after surgery for spontaneous supratentorial intracerebral, hemorrhage. A randomized, controlled, open-label, investigator-blinded pilot study.EUCTR2005-003083-36-ITOSPEDALE POLICLINICO S. MATTEO
进行中（未招募）
1 期
Recombinant Factor VIIa: Local treament of severe bleedings after deliverySevere postpartum bleedingMedDRA version: 16.1Level: LLTClassification code 10071867Term: Postpartum bleedingSystem Organ Class: 100000004868MedDRA version: 16.1Level: LLTClassification code 10071897Term: Third stage postpartum bleedingSystem Organ Class: 100000004868EUCTR2013-005036-20-DKStellaris Pharmaceuticals ApS
已完成
3 期
Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major BurnBurnsNCT00243243United States Army Institute of Surgical Research20